This work highlights the importance of host-mycobiome interactions in shaping inflammatory liver disease and supports further investigation into targeted strategies aimed at modulating IL-17A-mediated immune responses in patients with MASLD. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.